Connect with us

Published

on

Shares in UK housebuilders have taken a fresh hit on the latest woes to hit the sector including a profit warning from a major player.

Crest Nicholson shares plunged almost 15% at the start of Monday’s trading after it slashed adjusted pre-tax profit expectations for the year to October by more than 40% to £50m.

The Chertsey-based firm, which has lost more than a quarter of its market value in the year to date, blamed slowing sales as buyers battle high interest rates and inflation.

Cost of living – latest: House prices falling at double seasonal rate

Larger rivals saw their stocks come under pressure too.

Taylor Wimpey, Barratt Developments, Berkeley and Persimmon were the biggest fallers on the FTSE 100, with declines of more than 3% seen.

The market reaction also followed a Rightmove report showing a sharp fall in asking prices due to the twin squeeze on consumers.

More from Business

It said average asking prices fell by 1.9% over the past month, the biggest fall for August since 2018 and twice as steep as the typical summer holiday decline.

Rising mortgage costs caused sellers to lower their expectations of what they can get for their properties, the property website added.

Please use Chrome browser for a more accessible video player

‘I’m cutting everything out just to survive’

Nationwide Building Society had reported earlier this month that annual property values had declined by 3.8% in July, the sharpest fall since July 2009.

Data from Moneyfacts showed the average two-year fixed residential mortgage rate stood at 6.76% on Friday.

The five-year rate stood at 6.24%. Both were unchanged from the previous day.

They are linked to the funding costs faced by lenders as the Bank of England raises its key interest rate to battle inflation.

Financial markets believe it still has work to do, with Bank rate currently forecast to peak next year at 6% from the current 5.25%.

For its part, Crest Nicholson said transaction levels across the industry had weakened further, particularly in recent weeks, as mortgage borrowing turned more expensive.

“The group does not therefore expect to see a material improvement in trading conditions before its year end at 31 October,” it said.

Weekly sales volumes over the seven weeks to 18 Aug were at half the level the company had anticipated for the second half of the financial year.

The company had posted a profit of £137.8m in its 2022 fiscal year.

Read more: Job vacancies and starting salaries ‘fall for first time this year’ amid rate rise hit

AJ Bell investment director Russ Mould said of the market reaction: “Weak house price data is hardly a surprise.

“Economic uncertainty is elevated, mortgage costs have gone through the roof and the Help to Buy scheme has come to an end.

“However, Crest Nicholson’s profit warning has laid bare the scale of the impact of a housing slowdown on the housebuilding sector.

“Sales of new homes have plunged alarmingly and, while not all developers in the space are created equal, the news, allied to Rightmove’s latest reading on the property market, has had a knock-on effect on share prices in the rest of the sector this morning.

“The £7,000 drop in the average asking price observed by Rightmove in the last month, allied to a big drop in transaction volumes, is the kind of statistic to make estate agents distinctly uneasy.”

He added: “The scale of Crest Nicholson’s warning may come as a shock to investors given it reported its first half results just a couple of months ago and this hints at the speed and scale of the deterioration in the market.

“The one compensation for shareholders is Crest Nicholson is at least sticking with its planned full year dividend payment for now. However, its gloomy update will have set the market on alert for further warnings from its industry peers.”

Continue Reading

Business

How markets reacted to uncertainty over Rachel Reeves’s future

Published

on

By

How markets reacted to uncertainty over Rachel Reeves's future

The pound fell and state borrowing costs rose during a period of uncertainty over the chancellor’s future on Wednesday.

During Prime Minister’s Questions, Sir Keir Starmer declined to guarantee whether a visibly emotional Rachel Reeves would remain chancellor until the next election following the government’s welfare bill U-turn.

Money blog: Cash in your pocket set to change

Following his remarks, the value of the pound dropped and government borrowing costs rose, via the interest rate on both 10 and 30-year bonds.

Although market fluctuations are common, there was a reaction following Sir Keir’s comments in the Commons – signalling concern among investors of potential changes within the Treasury.

Please use Chrome browser for a more accessible video player

PM refuses to rule out tax rises

Sterling dropped to a week-long low, hitting $1.35 for the first time since 24 June. The level, however, is still significantly higher than the vast majority of the past year, having come off the near four-year peak reached yesterday.

While a drop against the euro, took the pound to €1.15, a rate not seen since mid-April in the aftermath of President Donald Trump’s tariff announcements.

More on Rachel Reeves

Read more:
No 10 backs Reeves and says she is ‘going nowhere’
Analysis: Emotional Reeves a painful watch

Meanwhile, the interest rate investors charge to lend money to the government, called the gilt yield, rose on both long-term (30-year) and ten-year bonds.

The UK’s benchmark 10-year gilt yield – so-called for the gilt edges that historically lined the paper they were printed on – rose to 4.67%, a high last recorded on 9 June.

And 30-year gilt yields hit 5.45%, a level not seen since 29 May.

Follow The World
Follow The World

Listen to The World with Richard Engel and Yalda Hakim every Wednesday

Tap to follow

Both eased back in the hours following – as a spokesperson for the prime minister attempted to quell speculation about the chancellor’s future.

Sky News understands the prime minister made clear to the chancellor that she has his “complete support” and remains integral to his project.

Ms Reeves has committed to self-imposed rules to reduce debt and balance the budget. Speculation around her future led investors to question the government’s commitment to balancing the books – and how they would do that.

The questions over her future came after the government scrapped the core money-saving component of its welfare bill, which had been intended to reduce spending in order to meet fiscal rules.

Continue Reading

Business

More bad news for Elon Musk as Tesla deliveries miss target again

Published

on

By

More bad news for Elon Musk as Tesla deliveries miss target again

Tesla’s woes have deepened as latest production and deliveries figures showed a greater fall than expected.

A total of 384,122 Teslas were delivered from April to June this year, a 13.5% drop on the same period last year and the second quarter of slumping output.

Wall Street analysts had expected Tesla to report about 1,000 more deliveries.

It’s bad news for Tesla chief executive Elon Musk in a week of attacks from President Donald Trump on him personally, as well as his companies.

Money blog: Customers to get up to £2,000 compensation from water companies

Mr Musk found himself on the wrong side of Mr Trump and the majority of US congresspeople in his opposition to the so-called big beautiful bill approved by the US Senate.

His criticism of the inevitable debt rises the bill will result in led Mr Trump threatening to end subsidies for Mr Musk’s numerous businesses and to deport him.

More on Electric Cars

Please use Chrome browser for a more accessible video player

Trump threatens to ‘put DOGE’ on Musk

His role as founder and chief executive of numerous businesses has made him the world’s richest man, according to Forbes.

As well as Tesla, Mr Musk founded space technology company SpaceX and Starlink. He also acquired the social media company Twitter, which he rebranded X.

It was the poor performance of Tesla that pushed him out of full-time politics and back to the Tesla offices.

Read more:
AstraZeneca exit is a frightening prospect for the City and the government
Santander bank deal could mean TSB name disappears from UK high street

After months of share price tumbles and protests at Tesla showrooms, sales drops and car defacings, Musk left his work with the Trump administration’s Department of Government Efficiency (DOGE).

Not everyone viewed the figures as negative.

Analysts at financial services firm Wedbush said: “Tesla’s future is in many ways the brightest it’s ever been in our view given autonomous, FSD [full self-driving], robotics, and many other technology innovations now on the horizon with 90% of the valuation being driven by autonomous and robotics over the coming years but Musk needs to focus on driving Tesla and not putting his political views first.”

After a 5% share price fall earlier this week when Mr Musk strayed back into political matters, Tesla stock rose 4.5% on Wednesday.

The latest financial details for Tesla will be published later this month.

In the first three months of the year, Tesla’s profits fell by 71% to $409m (£306.77m) from $1.39bn (£1.04bn). Revenues were also well below forecasts, dropping 9% to $19.3bn (£14.5bn).

Continue Reading

Business

AstraZeneca exit is a frightening prospect for the City and the government

Published

on

By

AstraZeneca exit is a frightening prospect for the City and the government

It’s a threat that will send a shiver down the spine of Downing Street and shake the City of London to its core.

Even the notion that AstraZeneca (AZ) – the UK’s most valuable listed company – is thinking of upping sticks and switching its stock market listing to America is a frightening prospect on many levels.

After all, if your biggest firm departs for Wall Street, what message does it send to an already bruised London stock market that has struggled to find its way since the UK’s vote to leave the European Union?

Money latest: Cash in your pocket set to change

The timing of the report in The Times that Pascal Soriot, the pharmaceutical company’s long-standing chief executive, is considering his own Brexit for the company, will not be lost on anyone.

The Treasury is under severe strain and the Starmer government, apparently focused on compromise given its welfare reform U-turns, bruised.

Ministers have been scrambling to get the support of business back, after a budget tax raid that has added to the cost of employing people in the UK, by launching a series of strategies to demonstrate a growth-led focus.

More from Money

Mr Soriot’s reported shift is the culmination of years of frustration over UK tax rates and support for business – though it could also remove a focus on his own remuneration as the highest-paid director of a UK-listed firm.

Astrazeneca Boss Pascal Soriot
Image:
Pascal Soriot has run AZ since 2012

AZ has its own gripes with Labour.

In January, the company cancelled a planned £450m investment in a vaccine factory on Merseyside, accusing the government of reneging on the previous Conservative administration’s offer of financial aid.

At the same time, it has been rebuilding its presence in the United States.

That speaks to not only a home market snub but also the election of a US president intent on protecting, as he sees it, America-based companies and jobs.

Donald Trump is threatening 25% tariffs on all pharma imports.

Please use Chrome browser for a more accessible video player

How Trump’s tariffs are biting

AZ has already promised a $3.5bn (£2.6bn) investment in US manufacturing by the end of 2026.

It has also rejoined the leading US drug lobby group, bolstering its voice in Washington DC.

There are sound reasons for bolstering its US footprint; more than 40% of AZ’s revenues are made in the world’s largest economy. Greater US production would also shield it from any duties imposed by Mr Trump and any MAGA successor.

Since Brexit, complaints among UK stock market constituents have been of low valuations compared to peers (with a weak pound also leaving them vulnerable to takeovers), weaker access to capital and poor appetite for new listings.

Wise, the money transfer firm, became the latest UK name to say that it intends to move its primary listing to the US just last month.

Pic: Europa Press via AP
Image:
Shein had been exploring a London flotation until it was blocked. Pic: Europa Press via AP

If followed through, it would tread in the footsteps of Flutter Entertainment and the building equipment suppler CRH – just two big names to have already left.

London was snubbed for a listing by its former chip-designing resident ARM back in 2023.

An initial public offering by Shein, the controversial fast fashion firm, had offered the prospect of the biggest flotation for the UK in many years but that was blocked by the Chinese authorities.

Efforts to bolster the City’s appeal, such as through the Financial Conduct Authority’s overhaul of listing rules and the creation of pension megafunds to aid access to capital, have also been boosted in recent months by investors in US companies taking a second look at comparatively low valuations in Europe.

Market analysts have charted a cash spread away from the US as a hedge against an erratic White House.

The Times report suggested that Mr Soriot’s plans were likely to face some opposition from members of the board, in addition to the UK government.

Pic: itock
Image:
The City of London has faced a series of challenges since Brexit Pic: iStock

AstraZeneca has not commented on the story. Crucially, it did not deny it.

But a government spokesperson said: “Through our forthcoming Life Sciences Sector Plan, we are launching a 10-year mission to harness the life sciences sector to drive long-term economic growth and build a stronger, prevention-focused NHS.

“We have already started delivering on key actions, from investing up to £600m in the Health Data Research Service alongside Wellcome, through to committing over £650m in Genomics England and up to £354m in Our Future Health.

“This is clear evidence of our commitment and confidence in life sciences as a driver of both economic growth and better health outcomes.”

Governments don’t comment on stories such as these, but you can bet your bottom dollar that the departure of your biggest firm by market value is not the message a government laser-focused on growth can afford to allow.

Continue Reading

Trending